Giovanni Caforio, Bristol Myers Squibb CEO (Nicolas Messyasz/Sipa via AP Images)
November 8, 2022 10:33 AM EST
FDA+
Manufacturing

FDA warns Bris­tol My­ers Squibb for im­prop­er­ly in­ves­ti­gat­ing con­t­a­m­i­na­tion at site that makes Abrax­ane

Zachary Brennan

Senior Editor

Fol­low­ing a 10-day in­spec­tion ear­li­er this year, the FDA has sent a warn­ing let­ter with sev­er­al point­ed ques­tions to a Phoenix-based site, which is run …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times